Literature DB >> 6292290

Immune deficiency in the X-linked lymphoproliferative syndrome. I. Epstein-Barr virus-specific defects.

S Harada, K Sakamoto, J K Seeley, T Lindsten, T Bechtold, J Yetz, G Rogers, G Pearson, D T Purtilo.   

Abstract

Eleven males with XLP were evaluated for EBV-specific antibodies during periods of 2 to 7 yr. Variable responses to EBV-specific antigens were found. All 11 patients had subnormal anti-EBNA titers, which probably reflected a T cell deficiency. The patients showed four different patterns in their anti-VCA response: 1) two boys who had experienced malignant lymphoma mounted no antibodies at all; 2) two patients showed intermittent anti-VCA titers; 3) four males had persistently elevated anti-VCA titers; and 4) three patients showed normal anti-VCA titers. ADCC against EBV-infected cells was abnormally low in six patients and was elevated in two patients given gamma-globulin. ADCC titers did not correlate with anti-VCA titers. However, most patients with XLP failed to effect regression of autologous EBV-infected lymphoblastoid cell lines, indicating a deficiency in long-lived T cell-mediated immunity to EBV.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6292290

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Defective generation of killer cells against spontaneously Epstein-Barr virus (EBV)-transformed autologous B cells in a fatal EBV infection.

Authors:  M Yanagisawa; M Kato; K Ikeno; T Kobayashi; Y Miyagawa; A Komiyama; T Akabane
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

Review 2.  Control of viral disease: the development of Epstein-Barr virus vaccines.

Authors:  A J Morgan
Journal:  Springer Semin Immunopathol       Date:  1991

3.  α-Helix peptides designed from EBV-gH protein display higher antigenicity and induction of monocyte apoptosis than the native peptide.

Authors:  Mauricio Urquiza; Johanna Melo-Cardenas; Tatiana Guevara; Ignacia Echeverria; Isabel C Rodriguez; Magnolia Vanegas; Mario Amzel; Manuel E Patarroyo
Journal:  Amino Acids       Date:  2010-05-16       Impact factor: 3.520

Review 4.  X-linked lymphoproliferative disease (XLP) as a model of Epstein-Barr virus-induced immunopathology.

Authors:  D T Purtilo
Journal:  Springer Semin Immunopathol       Date:  1991

5.  Characterization of Ly108 in the thymus: evidence for distinct properties of a novel form of Ly108.

Authors:  Mala Dutta; Pamela L Schwartzberg
Journal:  J Immunol       Date:  2012-03-05       Impact factor: 5.422

6.  Inhibition of Epstein-Barr virus-mediated capping of CD21/CR2 by alpha interferon (IFN-alpha): immediate antiviral activity of IFN-alpha during the early phase of infection.

Authors:  A X Delcayre; M Lotz; W Lernhardt
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

7.  Human B lymphocytes immortalization by Epstein-Barr virus in the presence of cyclosporin A.

Authors:  F Pelloquin; J P Lamelin; G M Lenoir
Journal:  In Vitro Cell Dev Biol       Date:  1986-12

Review 8.  X-linked lymphoproliferative disease: genetic lesions and clinical consequences.

Authors:  Andrew J MacGinnitie; Raif Geha
Journal:  Curr Allergy Asthma Rep       Date:  2002-09       Impact factor: 4.806

Review 9.  XLP: clinical features and molecular etiology due to mutations in SH2D1A encoding SAP.

Authors:  Stuart G Tangye
Journal:  J Clin Immunol       Date:  2014-08-02       Impact factor: 8.317

10.  Heterogeneity of immune defects in three children with a chronic active Epstein-Barr virus infection.

Authors:  W Kuis; J J Roord; B J Zegers; A B Rickinson; J G Kapsenberg; H The; J W Stoop
Journal:  J Clin Immunol       Date:  1985-11       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.